Iovance Biotherapeutics Inc. is a leading biotechnology company specializing in the development of novel cancer immunotherapies. Leveraging its expertise in Tumor Infiltrating Lymphocytes (TILs), the company aims to revolutionize cancer treatment by harnessing the power of the immune system to eradicate tumors. With a strong pipeline and promising clinical trial results, Iovance Biotherapeutics is poised to make a significant impact in the fight against cancer.